ANI Pharmaceuticals, Inc. Expected to Earn Q3 2024 Earnings of $0.75 Per Share (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Stock analysts at Capital One Financial upped their Q3 2024 earnings per share estimates for ANI Pharmaceuticals in a report issued on Thursday, September 19th. Capital One Financial analyst T. Chiang now expects that the specialty pharmaceutical company will earn $0.75 per share for the quarter, up from their previous estimate of $0.74. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.50 per share.

Other research analysts have also issued reports about the stock. Raymond James lifted their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Truist Financial reiterated a “hold” rating and issued a $60.00 price target (down from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Finally, StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $78.80.

ANI Pharmaceuticals Price Performance

ANIP opened at $59.66 on Monday. The firm has a 50-day moving average price of $61.07 and a 200-day moving average price of $63.68. ANI Pharmaceuticals has a twelve month low of $48.20 and a twelve month high of $70.81. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of 37.29 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The company had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. During the same quarter in the prior year, the company earned $1.06 EPS. The firm’s quarterly revenue was up 18.5% compared to the same quarter last year.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ANIP. Allspring Global Investments Holdings LLC increased its holdings in ANI Pharmaceuticals by 287.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock valued at $1,471,000 after purchasing an additional 15,790 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of ANI Pharmaceuticals by 106.9% during the first quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock valued at $1,434,000 after acquiring an additional 10,716 shares in the last quarter. Wakefield Asset Management LLLP purchased a new stake in ANI Pharmaceuticals in the first quarter worth $979,000. Sequoia Financial Advisors LLC bought a new stake in ANI Pharmaceuticals in the second quarter valued at $600,000. Finally, Lisanti Capital Growth LLC bought a new stake in ANI Pharmaceuticals in the first quarter valued at $2,218,000. Institutional investors own 76.05% of the company’s stock.

Insider Activity at ANI Pharmaceuticals

In other news, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction on Monday, July 1st. The shares were sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the completion of the sale, the senior vice president now directly owns 193,226 shares of the company’s stock, valued at approximately $12,258,257.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $63.44, for a total value of $1,268,800.00. Following the completion of the sale, the senior vice president now owns 193,226 shares in the company, valued at approximately $12,258,257.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Muthusamy Shanmugam sold 11,000 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $63.38, for a total value of $697,180.00. Following the transaction, the chief operating officer now directly owns 671,620 shares in the company, valued at $42,567,275.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 46,007 shares of company stock valued at $2,911,790. Company insiders own 12.70% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.